RAKUTEN MEDICAL RAISES $100 MILLION IN OVERSUBSCRIBED SERIES F TO ACCELERATE DEVELOPMENT TOWARD U.S. REGULATORY APPROVAL
Further company coverage: [ ]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.